Lotus Pharmaceuticals Inc. is a holding company incorporated in Nevada with its principal place of business in the People’s Republic of China (the “PRC”). We operate, control and beneficially own the pharmaceutical business of Lotus East. Lotus East develops, manufactures, markets and sells pharmaceutical products in the PRC. Lotus East produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Lotus East has established markets for several drugs that are self-branded or self-patented including (i) Maixin - valsartan capsules for the treatment of hypertension, (ii) Muxin – eye drops for the treatment of glaucoma and (iii) Yipubishan - octreotide Acetate Injection solution for the treatment of gastric ulcers. Lotus East’s drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Lotus East has a nationwide sales network to directly and indirectly sell to hospitals, clinics and drugs stores in approximately 30 provinces in China. Additionally, through its 10 retail pharmacy locations in Beijing, China, Lotus East sells western and traditional Chinese medications and medical treatment equipment.
Company profile
Ticker
LTUS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
S.e. Asia Trading Company, Inc.
SEC CIK
Corporate docs
IRS number
200507918
Latest filings (excl ownership)
8-K
Other Events
26 Feb 20
15-12G
Securities registration termination
11 May 12
NT 10-K
Notice of late annual filing
30 Mar 12
8-K/A
Entry into a Material Definitive Agreement
15 Mar 12
8-K
Entry into a Material Definitive Agreement
30 Jan 12
8-K
Departure of Directors or Certain Officers
11 Jan 12
8-K
Entry into a Material Definitive Agreement
9 Jan 12
8-K
Lotus Pharmaceuticals Announces Third Quarter 2011 Financial Results
16 Nov 11
10-Q
2011 Q3
Quarterly report
10 Nov 11
8-K
Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
17 Aug 11
Latest ownership filings
No filings